Rather than rely solely upon pupillary occlusion or tracking of eye movement to protect the fundus from accidental exposure to electromagnetic radiation, the present invention also utilizes an electromagnetic radiation pathway with a profile such that the energy density at the iris is greater than the energy density at the posterior portion of the eye. This disparity in energy density allows for efficacy at the anterior iris treatment site, without injury to the fundus.

Additive manufacturing techniques are used to form an artificial intra-ocular lens (IOL) directly inside the human eye. Small openings are formed in the cornea and lens capsule of the eye, and the crystalline lens is broken up and removed through the openings; then, a material is injected into the lens capsule through the openings, and the focal spot of a pulse laser beam is scanned in a defined pattern in the lens capsule, to transform the material in the vicinity of the lase focal spot to form the IOL in a layer-by-layer manner. In one embodiment, stereolithography techniques are used where a pulse UV laser source is used to photosolidify a photopolymer resin. The liquefied resin is injected into the eye through the openings, after which only part of the resin, having the shape of the desired IOL, is selectively cured with the UV laser beam, via progressive layer formation.

A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.

An adapter for coupling a laser treatment device to an object for treatment. The adapter has an input side, which may be fixed relative to the laser treatment device, by a locking mechanism and which may be fixed to the object, for alignment of the object relative to the laser treatment device. A scanned laser beam is introduced on the input side, from the laser treatment device, along a beam path to the object with a reference structure. The reference structure lies on the beam path of the adapter and may be optically detected by means of the laser beam scanned over the region.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be effected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

An apparatus, such as lenses, a system and a method for providing custom ocular aberrations that provide higher visual acuity. The apparatus, system and method include inducing rotationally symmetric aberrations along with an add power in one eye and inducing non-rotationally symmetric aberrations along with an add power in the other eye to provide improved visual acuity at an intermediate distance.

A method of verifying a laser scan at a predetermined location within an object includes imaging at least a portion of the object, the resulting image comprising the predetermined location; identifying the predetermined location in the image, thereby establishing an expected scan location of the laser scan in the image; performing a laser scan on the object by scanning a focal point of the laser beam in a scanned area; detecting a luminescence from the scanned area and identifying an actual scanned location within the image based on the detected luminescence; and determining whether the difference between the actual scanned location and the expected scan location is within a threshold value.

Provided herein are methods for non-invasive ophthalmic surgery based on femto second multi shooting (FSMS) laser techniques. In one embodiment the FSMS laser technique is directed to corneal stroma. In another embodiment the FSMS laser technique is directed to crystalline lens.

For processing eye tissue using a pulsed laser beam (L), an ophthalmological device includes a projection optical unit for the focused projection of the laser beam (L) into the eye tissue, and a scanner system upstream of the projection optical unit for the beam-deflecting scanning of the eye tissue with the laser beam (L) in a scanning movement (s) performed over a scanning angle along a scanning line(s). The projection optical unit is tilted about an axis of rotation (q) running perpendicularly to a plane defined by the scanning line(s) and the optical axis (o) of the projection optical unit, the tilting of the projection optical unit tilting the scanning line (s) in said plane. Tilting of the scanning line(s) enables a displacementdependent on the scanning angleof the focus of the laser pulses projected into the eye tissue without vertical displacement of the projection optical unit.

A system for ophthalmic surgery includes a laser source configured to deliver an ultraviolet laser beam comprising laser pulses having a wavelength between 320 nm and 370 nm to photodecompose one or more intraocular targets within the eye with chromophore absorbance. The pulse energy, the pulse duration, and the focal spot are such that an irradiance at the focal spot is sufficient to photodecompose the one or more intraocular targets without exceeding a threshold of formation of a plasma and an associated cavitation event. An optical system operatively coupled to the laser source and configured to focus the ultraviolet laser beam to a focal spot and direct the focal spot in a pattern into the one or more intraocular targets. The optical system focuses the laser beam at a numerical aperture that provides for the focal spot to be scanned over a scan range of 6 mm to 10 mm.